RXRX

Recursion Pharmaceuticals' stock experienced a decline of 25.51% over the past six months. Key events include a Q1 2026 earnings report with decreased revenue but a narrower net loss, positive Phase 1b/2 results for REC-4881, positive early Phase 1 data for REC-1245, and the first patient dosed in the Phase 1 study for REC-4539. JPMorgan trimmed its price target on RXRX. Recursion announced a board transition. The company reported Q4 2025 revenue with a significant year-over-year increase. There have been insider sales but no insider purchases of RXRX stock. The company announced the suspension of four trials and the pausing of one, reducing its pipeline to six programs.